CureVac N.V. Ordinary Shares (CVAC)
CureVac N.V. is a biotechnology company focused on the development of mRNA-based therapeutics and vaccines. Founded in Germany, it aims to revolutionize medicine through innovative mRNA technology, with a focus on infectious diseases, cancer, and rare diseases.
Company News
BioNTech reported Q2 sales of $295.7 million, exceeding expectations, with a narrowed per-share loss. The company strengthened its oncology strategy through a collaboration with Bristol Myers Squibb and plans to acquire CureVac.
The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.
While smaller deals have been completed, including overseas acquisitions, the expected surge in large-scale mergers and acquisitions has not materialized. Factors like trade policy uncertainty and economic concerns have kept corporate decision-makers cautious about striking major deals.
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Nvidia gains as Q1 results, guidance top expectations; announces 10-1 split. Live Nation sinks 7% on report DOJ antitrust action is ready. Moderna, BioNTech close double-digits.